Zura Bio Limited — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report; the supplied filing does not provide a clear standalone Q4 income statement or cash-flow comparison. The prior-period comparison is January 18, 2022 (inception) through December 31, 2022, so it is not a full-year comparison.
Business context
Zura is a clinical-stage immunology company with no approved products and no product revenue. Its three principal candidates are tibulizumab (ZB-106), ZB-168 and torudokimab (ZB-880). The company completed its business combination and began trading on Nasdaq in March 2023, and raised $80.0 million gross in an April 2023 private placement.
Financial performance and position
| Metric | FY2023 | Prior reported period |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $44.0 million | $23.7 million |
| General and administrative expense | $18.6 million | $3.5 million |
| Total operating expenses | $62.6 million | $27.2 million |
| Net loss | $60.4 million | $25.7 million |
| Net loss attributable to Class A ordinary shareholders | $69.2 million | $32.4 million |
| Net loss per share, basic and diluted | $2.09 | $141.97 |
| Cash and cash equivalents at year-end | $99.8 million | $1.6 million |
| Net cash used in operating activities | $15.1 million | $1.2 million |
| Net cash used in investing activities | $8.0 million | $12.0 million |
| Net cash provided by financing activities | $121.3 million | $14.8 million |
At December 31, 2023, total assets were $100.8 million, total liabilities $21.3 million, and redeemable noncontrolling interest $18.7 million. The $7.8 million note payable reported at the prior year-end was repaid for $10.0 million at the March 2023 business-combination closing; no note payable remained at year-end 2023. No conventional gross margin is reported because Zura had no product sales.
Changes, outlook and notable items
- R&D expense rose 86% and G&A expense rose 437% versus the shorter 2022 inception period. The increases reflect licensed-asset acquisition costs, manufacturing and clinical-development activity, compensation and public-company costs.
- FY2023 R&D included $27.4 million related to the 2023 Lilly license and related items, including a $5.0 million finder’s fee; acquired in-process R&D was expensed. The company also recorded a $10.9 million deemed dividend and a $9.2 million deemed contribution associated with changes to Stone Peach’s redeemable noncontrolling interest. These items affected loss attributable to ordinary shareholders.
- Management says existing cash, cash equivalents and short-term marketable securities are expected to fund operations through 2026; the balance sheet reports $99.8 million in cash and cash equivalents and does not separately show short-term marketable securities. The estimate depends on assumptions and may prove inaccurate. The company has no committed external funding source and expects further losses and additional financing needs.
- Zura plans to initiate a Phase 2 systemic sclerosis study for tibulizumab in the second half of 2024. It is preparing ZB-168 and torudokimab for potential Phase 2 development, while evaluating indications and external clinical developments. No quantitative financial guidance was provided.
- Torudokimab’s Phase 2 atopic dermatitis study was terminated early for lack of efficacy, not safety. ZB-168 previously had an FDA clinical hold, lifted in 2016 with conditions; the filing says the FDA’s September 2023 response acknowledged nonclinical work that appeared reasonable to support a Phase 2 study in alopecia areata.
- All candidates depend on third-party manufacturing. WuXi Biologics in China is currently the sole supplier of torudokimab; the company cites potential geopolitical, regulatory and supply disruption risks. Tibulizumab manufacturing processes were transferred to Patheon, and ZB-168 manufacturing materials were undergoing release or quality-control steps for future studies.
- Material contingent economics include Pfizer development/regulatory milestones up to $70 million and sales milestones up to $525 million; Lilly milestone obligations include up to $155 million in development milestones and up to $440 million in sales milestones for each applicable Lilly license, plus royalties. The amounts and timing depend on future development and sales. Some additional third-party fees and royalties also apply.
- CEO Someit Sidhu is scheduled to step down on April 8, 2024, remaining on the board; President and COO Robert Lisicki is scheduled to become CEO. The filing says the transition is not due to a disagreement.
Risks and controls
The principal risks are clinical failure or delay, regulatory uncertainty, financing and dilution, dependence on Pfizer and Lilly licenses, third-party manufacturing and trial providers, competition, and intellectual-property challenges. The company reported an accumulated deficit of $103.5 million and recurring losses. The audited financial statements received an unqualified opinion. Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2023; the auditor did not provide an internal-control attestation because Zura is an emerging growth company. A prior material weakness relating to complex financial instruments and accounting for IPO proceeds was disclosed in connection with the earlier auditor transition.
Investor verification priorities
- Confirm the cash balance, actual quarterly burn, and assumptions supporting the stated runway through 2026.
- Track timing, enrollment, manufacturing readiness and results for the planned tibulizumab Phase 2 study and future programs.
- Review the economics, milestones, royalties, termination provisions and third-party obligations in the Pfizer and Lilly licenses, including amounts recognized or accrued.
- Assess potential dilution: 43.6 million Class A shares were outstanding as of March 26, 2024; the filing also lists substantial warrants, options, equity awards and a 2.0 million-share Stone Peach put right.
- Monitor torudokimab’s sole-source supply exposure to WuXi, manufacturing transfers and any relevant U.S.–China policy developments.
- Verify execution of the CEO transition and continued development of financial-reporting and compliance processes.